A case of dabigatran-associated acute renal failure

Wisconsin Medical Journal

Volumn 112, Issue 4, 2013, Pages 173-176

  Shafi, Salman Tahir ^a,b   Negrete, Hilmer ^b   Roy, Prakash ^b   Julius, Carmen J ^a,b   Sarac, Erdal ^a,b  

^a Northeast Ohio Medical University   (United States)

^b ST ELIZABETH HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CREATININE; DABIGATRAN; HEMOGLOBIN; NITROGEN; PREDNISOLONE; ROSUVASTATIN; UREA; VALSARTAN; VITAMIN D;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CHOLESTEROL EMBOLISM; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; DOPPLER FLOWMETRY; DRUG WITHDRAWAL; ECHOGRAPHY; ELDERLY CARE; ERYTHROCYTE COUNT; FATIGUE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; KIDNEY ARTERY STENOSIS; KIDNEY BIOPSY; MALE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PHYSICAL EXAMINATION; PROTHROMBIN TIME; RARE DISEASE; REPEAT PROCEDURE; THROMBIN TIME; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ACUTE KIDNEY INJURY; AGED; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BIOPSY; HUMANS; MALE; RENAL DIALYSIS;

EID: 84881633095     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Spinler S. The Pharmacology and Therapeutic Use of Dabigatran Etexilate [Epub ahead of print January 31, 2012]. J Clin Pharmacol. doi:10.1177/0091270011432169.
2. Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010;375(9726):1650-1660.
3. Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation. 2007;116(3):298-304.
4. Feder W, Auerbach R. "Purple toes": an uncommon sequela of oral coumarin drug therapy. Ann Intern Med. 1961;55:911-917.
5. Schwarz MW, McDonald GB. Cholesterol embolization syndrome. Occurrence after intravenous streptokinase therapy for myocardial infarction. JAMA. 1987;258(14):1934-1935.
6. Blackshear JL, Zabalgoitia M, Pennock G, et al. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. Am J Cardiol. 1991;83(3):453455.
7. Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol. 2002;90(12):1320-1325.
8. Pradaxa [prescribing information]. Ingelheim, Germany: Boehringer Ingelheim; 2012. http://www.pradaxa.com. Accessed July 8, 2013.
9. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127.
10. Iyer V, Singh HS, Rieffel JA. Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use. J Cardiovasc Pharmacol Ther. 2012;17(3):237-247. doi:10.1177/1074248412436608
11. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105(2):371-378.
12. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107(5):985-997.
13. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal Bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46(4):e10. doi: 10.1345/aph.1Q747
14. Béné J, Saïd W, Rannou M, Deheul S, Coupe P, Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46(6):e14. doi:10.1345/aph.1Q705
15. Stangier J, Rathgen K, Stähle H, Masur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259-268.